Translational control in heart and lung disease by rnase a family

Active Project Grant Awarded Last action

Award ID
F31HL180041
Recipient
Awarding agency
Obligated
$103,686

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 34% complete
Place of performance
Worcester, MA 01655, USA

Award details come from USAspending.gov.

About this award

The National Heart, Lung, and Blood Institute awarded University of Massachusetts Medical School $103,686 on December 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support basic research into translation control mechanisms in heart and lung disease.

The funded research investigates how the RNase A family nuclease angiogenin stimulates blood vessel formation and why angiogenin dysfunction associates with heart failure, and separately examines how the bacterial nuclease ribocin, encoded by Pseudomonas aeruginosa, damages human ribosomes and triggers inflammatory and cell-death responses in lung tissues. The project aims to determine the structural basis of translation control by angiogenin during angiogenesis and measure the impact of translation control by ribocin on ribotoxic stress response and cell death. Work is performed at Worcester, Massachusetts with a period of performance through June 30, 2028. This is a project grant, a training award supporting a junior investigator under mentor guidance using cutting-edge cryo-electron microscopy and structural biology methods to inform future therapeutic approaches to cardiovascular disease and post-infection pulmonary damage.

Description

Abstract
Cardiovascular disease is the leading cause of death in the united states. Despite decades of research, IT is unclear how the rnase a family nuclease angiogenin stimulates blood vessel formation, and why angiogenin dysfunction is associated with heart failure and poor cardiovascular health. Recent work revealed that angiogenin's nuclease activity, which is required for its angiogenic function, is stimulated by binding to the ribosome, but IT remains unclear whether angiogenin's ribosome-dependent mechanism is involved in angiogenesis. A bacterial nuclease named ribocin with a strikingly angiogenin-like structure and ribosome- dependent activity holds similar potential for understanding lung health. Nearly all cystic fibrosis patients experience pseudomonas aeruginosa bacterial pneumonia and subsequently suffer from lung tissue inflammation and lasting damage long after the infection has cleared. Ribocin encoded by p. Aeruginosa damages human ribosomes specifically at central helix 69 of the 28S rrna and inhibits translation. We hypothesize that like other ribosome-inactivating proteins, ribocin induces a ribotoxic stress response that causes inflammation and cell death in human lung tissues. To inform future therapeutic studies aimed at treating cardiovascular disease and post-infection pulmonary damage, the mechanisms of translation control by these rnase a-family nucleases must be elucidated in the context of their cellular functions. The goal of this project is to determine the structural basis of translation control by angiogenin during angiogenesis and determine the impact of translation control by ribocin on ribotoxic stress response and cell death. With guidance from the sponsor, an expert in biochemical and structural basis of translation, and collaborators, who are experts in the RNA developmental biology and cryo-EM method development, the trainee will apply cutting edge methods for in-cell cryogenic electron microscopy (cryo-EM) complemented by cell assay and biochemical approaches to visualize structural changes to actively translating ribosomes during angiogenin- stimulated vascularization and ribocin-mediated tissue damage. Aim 1 will determine the contribution of angiogenin's ribosome-specific activity on tube formation (angiogenesis) in human umbilical vascular endothelial cells (huvec). Aim 2 will elucidate the structural mechanism of translation inhibition by ribocin and investigate the impact of selective ribosome damage by ribocin on ribotoxic stress response in human lung cells (IB3). The results of this study will reveal details of mechanisms underlying fundamental cardiovascular function and novel components of pulmonary disfunction, necessary for future work in developing therapeutics for cardiovascular and lung disease.

Transactions

Action Obligated Date
Amendment $34,946
Amendment $34,370
Amendment $0
Original award $34,370

Quick answers

Who received award F31HL180041?

F31HL180041 was awarded to University Of Massachusetts Medical School by National Heart Lung and Blood Institute (National Institutes of Health) on December 12, 2025.

How much is award F31HL180041 worth?

$103,686 has been obligated on F31HL180041.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award